Clinical trials
Cancer Patients clinical trials
Below are recruiting cancer patients clinical trials, each written for real people, not researchers. We’re tracking 3,537 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06219083Recruiting
Nutrition and outcomes in common cancers
This study looks at how nutrition affects recovery and results in people getting chemotherapy or radiation for common cancers. It may help improve care by tracking what you eat and how your body responds.
Xi'an, ShaanxiAges 18 years+ - NCT06200558Recruiting
Study of treatments for advanced prostate cancer
This study looks back at the experiences of men with prostate cancer that has spread to other parts of the body. It aims to learn which treatments—such as hormone therapy combined with other drugs, or a radioactive therapy—work best for different types of advanced prostate cancer.
Province of Macerata, MacerataAges 18 years+ - NCT05973864RecruitingPhase 2
Capecitabine plus pembrolizumab after TNBC surgery and chemo
This Phase 2 trial studies whether adding capecitabine to pembrolizumab after surgery can lower the risk of cancer coming back in people with triple-negative breast cancer that didn’t fully respond to earlier treatment. It’s meant for patients whose tumor was removed but still showed remaining cancer after chemo-immunotherapy.
AmiensAges 18 years+ - NCT06007846RecruitingPhase 2/Phase 3
Memantine for advanced liver cancer and cirrhosis
This trial tests if memantine, a medication typically used for memory problems, can help people with advanced liver cancer and cirrhosis. It is for those who cannot have standard aggressive treatments.
Fairfax, VirginiaAges 18 years+ - NCT05775939Recruiting
PET/CT scan study to track heart damage from cancer radiation
This study uses a special scan (PET/CT) to look for early heart (cardiac) injury caused by radiation treatment for lung or esophageal cancer. If you may be at higher heart risk from your planned radiation dose, the scan may help researchers better measure that damage over time.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05715684Recruiting
Pre-surgery preparation program for people having bladder removal
This study tests a patient-centered coaching and preparation program before bladder surgery (cystectomy) to help you get ready for surgery and recovery. It may be especially helpful for people having urinary diversion using an ileal conduit or ileal neobladder.
Boston, MassachusettsAges 18–85 - NCT05558644Recruiting
Study immune and tumor features in thymus tumors
This study looks at what immune cells and tumor biology are like in localized thymic epithelial tumors. It may help doctors better understand the disease using samples taken during planned thymus surgery.
ParisAges 18 years+ - NCT02734069Recruiting
Testing whether muscle mass affects carboplatin side effects
This study looks at how your body’s “fat-free mass” (mostly muscle and organs) may change the dose of carboplatin and the risk of chemotherapy side effects. It’s for people with advanced lung cancer who are starting treatment with carboplatin plus paclitaxel for the first time.
Mexico CityAges 18 years+ - NCT05148156Recruiting
Urolift before radiation to reduce urinary side effects
This study tests whether a procedure called Urolift (which gently opens the prostate to relieve urinary blockage) before radiation therapy (SBRT) can reduce urinary side effects for men who have both prostate cancer and an enlarged prostate. If you qualify, you might experience fewer urinary problems during and after your cancer treatment.
Syosset, New YorkAges 50–99 - NCT04499365RecruitingEarly Phase 1
PET scan for detecting different cancer types
This trial uses a special PET scan to see how well it can find and track different types of cancer. It may help doctors better understand your cancer.
Fuzhou, FujianAges 18–90 - NCT04410302Recruiting
Personalized tumor research for bladder, lung, stomach, and liver cancers
This study uses a small sample of your tumor to grow it in the lab, which may help researchers understand your cancer better and find treatments that work for you.
Orange, CaliforniaAges 21–100 - NCT04370574Recruiting
Testing blood or tissue markers for suspected pancreatic cancer
This trial looks for “soluble biomarkers” (markers that can be found in body fluids like blood) for people who have a pancreatic mass and may have pancreatic ductal adenocarcinoma. The goal is to improve how pancreatic cancer is identified, especially using information taken from an endoscopic ultrasound biopsy.
Montpellier, MontpellierAges 18 years+ - NCT04085029Recruiting
Study registry for patients getting focused radiation for spread disease
This study keeps a registry (a record) of people with metastatic (spread) cancer who are receiving focused, high-dose radiation to body sites outside the brain. It aims to better understand outcomes and care patterns for these patients.
Cary, North CarolinaAges 18 years+ - NCT05746897RecruitingPhase 1
First-in-human test of an anti-PVRIG drug for advanced cancers
This early-phase study tests NM1F (an anti-PVRIG antibody) in people with advanced solid tumors to see if it’s safe and whether it may work. It also includes pembrolizumab (a PD-1 “checkpoint” medicine), aiming to boost the immune system against the cancer.
Dallas, TexasAges 18 years+ - NCT05997017RecruitingPhase 2
Nab-sirolimus plus letrozole for advanced endometrial cancer
This trial tests a combination of two drugs—nab-sirolimus and letrozole—for people with advanced or returning endometrioid endometrial cancer. The goal is to see if this combination can shrink tumors or slow cancer growth.
Little Rock, ArkansasAges 18 years+ - NCT07558733RecruitingPhase 1/Phase 2
New drug combinations for advanced hormone-receptor positive breast cancer
This trial tests two new drugs (sapanisertib and serabelisib) alone or together to treat advanced breast cancer that is hormone-receptor positive. These drugs target specific pathways that help cancer grow, and the trial will see if they work better than standard treatments.
Los Angeles, CaliforniaAges 18 years+ - NCT06749015Recruiting
Study for BRAFV600E Mutant Metastatic Colorectal Cancer
This trial tests a treatment for people whose colorectal cancer has spread and cannot be removed by surgery, and who have a specific gene change called BRAFV600E. It aims to find out if the treatment can help shrink or control the cancer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07513311Recruiting
Nurse Support Program for Triple-Negative Breast Cancer
This study tests a nurse-led coping and support program for people who recently finished treatment for triple-negative breast cancer. The program is designed to help you manage stress and emotional distress after treatment.
Boston, MassachusettsAges 18 years+ - NCT07173985Recruiting
Mailed colon cancer screening in Appalachia
This trial sends home a stool-based screening test to people in Appalachian counties. It aims to find the best way to help more people get screened for colon cancer.
Columbus, OhioAges 45–74 - NCT06931626RecruitingPhase 1
Study of NMS-03305293 for relapsed small cell lung cancer
This trial tests a new drug, NMS-03305293, in adults with small cell lung cancer that has come back after earlier treatments. The goal is to see if it can help shrink or slow the cancer.
Peoria, IllinoisAges 18 years+ - NCT06460298RecruitingPhase 1/Phase 2
ProAgio and gemcitabine for triple-negative breast cancer that has spread
This trial tests a new drug called ProAgio combined with the chemotherapy gemcitabine for people with triple-negative breast cancer that has spread to other parts of the body. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Atlanta, GeorgiaAges 18 years+ - NCT06217874Recruiting
Collecting Samples and Data for Recurrent or Metastatic Breast Cancer
This study collects tissue samples and health information from people with breast cancer that has spread or come back. It aims to help researchers learn more about the disease and may lead to better treatments.
Rochester, MinnesotaAges 18 years+ - NCT05942001RecruitingPhase 1
Testing an investigational drug for advanced prostate cancer
This Phase 1 trial tests HRS-5041 in people with metastatic castration-resistant prostate cancer (prostate cancer that keeps growing despite lower testosterone). It aims to see if the drug can be given safely and whether it may help control the cancer after prior standard treatments.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT05909332RecruitingPhase 3
Tested antivascular drug plus chemo versus chemo alone for TNBC
This Phase 3 trial compares an “anti-blood-vessel” drug added to chemotherapy versus chemotherapy alone for people with stage II–IIIC triple-negative breast cancer that has been completely removed with surgery. The goal is to see if adding the study drug improves outcomes after surgery (adjuvant treatment).
Beijing, Beijing MunicipalityAges 18–70
Hear when a new Cancer Patients trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for cancer patients?
- Yes. Clin2 currently lists 3,537 recruiting cancer patients studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a cancer patients trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a cancer patients trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.